Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the Canadian launch of Beteflam™ (betamethasone valerate), a novel, patent-protected patch,...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Ralph Bohrer has joined the Company in the position of President and General Manager of its U.S....

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at two upcoming...

Q4 revenue up 30%, Company significantly advances strategic plans to build a dermatology growth company MISSISSAUGA, ON, Feb. 24, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH)...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the Canadian launch of Actikerall™ (0.5% fluorouracil and 10% salicylic acid), indicated for the...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that its New Drug Submission for Sitavig™ has been accepted for review by Health Canada. Sitavig...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it will host a conference call for its Q4 and full-year 2015 financial results on Wednesday, February...

– Will Represent Fourth Commercial Product in Cipher's Growing Canadian Dermatology Business – MISSISSAUGA, ON, Dec. 7, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH)...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, and Norman Evans, Chief Financial...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will be presenting at the TD...

– Quarter Highlighted by 28% Revenue Growth, $2.3 Million in Cash Flow from Operations and Strong Advancement of Pre-Commercial Portfolio – MISSISSAUGA, ON, Nov. 4, 2015 /CNW/ - Cipher...

Cipher Pharmaceutiquired to build its commercial infrastructure in Canada. ____________________ 1 Source: IMS Health. Market share calculated based on total isotretinoin prescriptions. Product...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Company, along with its partners, Ranbaxy Pharmaceuticals, Inc. ("Ranbaxy"), a Sun Pharma...

– Quarter Highlighted by Continued Solid Performance from Isotretinoin Products and Acquisition and Integration of Innocutis – MISSISSAUGA, ON, Aug. 14, 2015 /CNW/ - Cipher Pharmaceuticals...

- Acceptance marks first regulatory filing with FDA since Absorica® in 2011 - MISSISSAUGA, ON, Aug. 4, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company")...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q2 2015 financial results on Friday, August 14, 2015. Q2 2015 CONFERENCE CALL WHEN:...

- Company expects to submit Ozenoxacin for regulatory approval in Canada in the first quarter of 2016 - MISSISSAUGA, ON, July 30, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH)...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the 2015 JMP Securities Life Sciences...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the BIO International Convention in...

- Company Adds Regulatory and Alliance Management Expertise to Support Expanded Product Portfolio - MISSISSAUGA, ON, June 2, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH)...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the Jefferies 2015 Global Healthcare Conference in

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special...

– Company Achieves Significant Progress Across All Three Components of Growth Strategy – MISSISSAUGA, ON, May 13, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa®...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q1 2015 financial results and hold its Annual and Special Meeting of Shareholders on...